Rituximab, by depleting CD19+ and CD20+ B cells, has been utilized to treat B‐cell lymphomas since 1997 and is also effective for treating rheumatoid arthritis and membranous nephropathy [17–19]. This evidence concerns the gene CD19 and membranous glomerulonephritis.